news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

1. termination of ipo review! a-share equity financing slows down

so far this year, both the number and total amount of financing projects have dropped by more than 60% compared with last year. in addition, ophis and its sponsor voluntarily withdrew their listing application, and the shenzhen stock exchange also decided to stop reviewing its ipo on the main board.

in addition to ophis, the ipo plans of companies such as bio-pharmaceutical, bio-pharma, and green biotech have also been terminated. what is more worth mentioning is that in the first four months alone, the number of new listings and the amount of funds raised fell sharply by 66% and 77% year-on-year. it is worth mentioning that the number of new listings and the amount of funds raised in the first four months fell by 66% and 77% year-on-year, respectively, which undoubtedly shows that a large number of ipo plans are currently on hold.

2. juzi biopharma's revenue seems to be too dependent on kefumei, and it may be difficult to solve its development difficulties.

although juzi bio's revenue and net profit increased in the first half of the year, the financial report shows that the revenue share of this brand has soared from 68% in 2022 to more than 80% now. at the same time, the performance growth of aimei and haohai bio is also slowing down, and huaxi bio has suffered the worst half-year since its listing.